Grifols' key therapeutic areas include immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases. Grifols' extensive portfolio addresses conditions such as primary immunodeficiencies, hemophilia, and chronic liver diseases. 

Operating in more than 110 countries, Grifols has a significant presence across Europe, North America, and Asia-Pacific. The company manages a robust network of plasma donation centers and manufacturing facilities worldwide, ensuring a reliable supply of life-saving therapies. 

In December 2024, Grifols completed a private placement of €1.3 billion in senior secured notes due May 2030, with an interest rate of 7.125%. This transaction aimed to refinance existing debt maturing in February 2025 and extend the company's revolving credit facility to May 2027, significantly enhancing liquidity and financial stability. 

Additionally, in November 2024, Grifols concluded discussions with Brookfield Asset Management regarding a potential acquisition. The board determined that Brookfield's valuation of €6.45 billion significantly undervalued the company's prospects and long-term potential, leading to the termination of talks.